Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie M Warholic

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 5, 2005
E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia modelThomas A Russo, Bruce A Davidson, Stacy A Genagon, et al.
ACS Chemical Biology|August 26, 2014
Reaction coupling between wild-type and disease-associated mutant EZH2Brooke M Swalm, Sarah K Knutson, Natalie M Warholic, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2013
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Sarah K Knutson, Natalie M Warholic, Tim J Wigle, et al.
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Cancer Therapeutics|August 25, 2017
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCLDorothy Brach, Danielle Johnston-Blackwell, Allison Drew, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
American Journal of Physiology. Lung Cellular and Molecular Physiology|April 5, 2005
E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia modelThomas A Russo, Bruce A Davidson, Stacy A Genagon, et al.
ACS Chemical Biology|August 26, 2014
Reaction coupling between wild-type and disease-associated mutant EZH2Brooke M Swalm, Sarah K Knutson, Natalie M Warholic, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 27, 2013
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2Sarah K Knutson, Natalie M Warholic, Tim J Wigle, et al.
Plos One|January 14, 2017
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Molecular Cancer Therapeutics|August 25, 2017
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCLDorothy Brach, Danielle Johnston-Blackwell, Allison Drew, et al.
Plos One|July 9, 2016
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial SarcomaSatoshi Kawano, Alexandra R Grassian, Masumi Tsuda, et al.
Plos One|December 11, 2014
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin LymphomasSarah K Knutson, Natalie M Warholic, L Danielle Johnston, et al.
ACS Medicinal Chemistry Letters|May 26, 2015
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo ActivityJohn E Campbell, Kevin W Kuntz, Sarah K Knutson, et al.
Nature Chemical Biology|October 2, 2012
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cellsSarah K Knutson, Tim J Wigle, Natalie M Warholic, et al.
Molecular Cancer Therapeutics|February 25, 2014
Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphomaSarah K Knutson, Satoshi Kawano, Yukinori Minoshima, et al.
Pageof 1